Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
Open Access
- 7 November 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (22) , 6961
Abstract
The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg). This narrative review examines and compares SCIg versus IVIg in chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but is better tolerated and easier to administer, as intravenous access is not required. Furthermore, SCIg administration is more convenient and cost-effective than IVIg, enabling flexible treatment scheduling at home and improving patients’ overall quality of life. The availability of highly concentrated immunoglobulin G (IgG) subcutaneous solutions, such as IgPro20, a 20% IgG solution stabilized with L-proline, allows for the administration of larger volumes in a single session, while the parallel development of new technological devices enables the delivery of higher doses over a shorter time. Based on the results of the PATH study, SCIg has become a well-established therapy in CIDP. In addition to discussing the advantages of SCIg, this review summarizes the evolution of SCIg by discussing all the relevant clinical studies which have considered its use in the treatment of CIDP.Keywords
This publication has 53 references indexed in Scilit:
- The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulinJournal of the Peripheral Nervous System, 2011
- Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE studyJournal of the Peripheral Nervous System, 2010
- Subcutaneous immunoglobulin: opportunities and outlookClinical and Experimental Immunology, 2009
- Incidence and prevalence of CIDP and the association of diabetes mellitusNeurology, 2009
- Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK populationMuscle & Nerve, 2009
- Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese populationJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in ItalyJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathyMuscle & Nerve, 2007
- Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficienciesCurrent Opinion in Allergy and Clinical Immunology, 2006
- The Italian SF-36 Health SurveyJournal of Clinical Epidemiology, 1998